Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax Monotherapy or with Rd in Relapsed/Refractory Multiple Myeloma
NCT04674514Phase 2Unknown
- Sponsor
- Ascentage Pharma
- Start
- Apr 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in multiple myeloma (MM), sponsored by Ascentage Pharma. Status: unknown.
02
Drugs
lisaftoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04674514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674514.